Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Westin

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|January 22, 2024
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvementAnath C Lionel, Ashwath Gurumurthi, Ahmed Fetooh, et al.
Haematologica|May 11, 2019
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasPaolo Strati, Loretta J Nastoupil, Richard E Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2018
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasLan V Pham, Shengjian Huang, Hui Zhang, et al.
Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.
Leukemia & Lymphoma|August 26, 2021
A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphomaHua-Jay J Cherng, Hubert H Chuang, Raphael Steiner, et al.
Blood Advances|February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 studyJason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Haematologica|November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomaRaphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
JAMA Oncology|July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled TrialChelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Blood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
Haematologica|August 1, 2020
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphomaPaolo Strati, Ankur Varma, Sherry Adkins, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|January 22, 2024
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvementAnath C Lionel, Ashwath Gurumurthi, Ahmed Fetooh, et al.
Haematologica|May 11, 2019
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasPaolo Strati, Loretta J Nastoupil, Richard E Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2018
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasLan V Pham, Shengjian Huang, Hui Zhang, et al.
Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.
Leukemia & Lymphoma|August 26, 2021
A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphomaHua-Jay J Cherng, Hubert H Chuang, Raphael Steiner, et al.
Blood Advances|February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 studyJason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Haematologica|November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomaRaphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
JAMA Oncology|July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled TrialChelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Blood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
Haematologica|August 1, 2020
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphomaPaolo Strati, Ankur Varma, Sherry Adkins, et al.
Pageof 10